Transaction details
On March 25, 2026, Yeleswaram Krishnaswamy, Rapport Therapeutics, Inc. (NASDAQ: RAPP) Chief Development Officer, sold 10,115 shares of the company’s common stock for an aggregate of approximately $303,354. Reported execution prices for the transactions ranged from $29.90 to $30.18 per share. The disposition was carried out under a prearranged Rule 10b5-1 trading plan that the executive adopted on December 10, 2025.
Post-sale ownership
Following the sale, Krishnaswamy retains direct ownership of 286,876 shares of Rapport Therapeutics common stock.
Context on market performance and valuation
The company’s shares have delivered a 198% return over the past year. The stock currently trades above its Fair Value estimate, according to the data referenced in the company’s disclosures.
Clinical progress and company announcements
Rapport Therapeutics released fiscal year 2025 results in the wake of Phase IIa clinical data for RAP-219 in focal seizures. Management also announced plans to accelerate phase 3 trials for RAP-219, moving those studies into the second quarter of 2026.
Analyst reactions
Several firms have responded to the company’s announcements by maintaining or adjusting their Buy ratings and price targets. Stifel and Jones Trading reaffirmed Buy ratings with price targets of $56.00 and $50.00, respectively. Truist Securities reiterated its Buy rating and set a $44.00 target after the company said it would accelerate its phase 3 timeline. BTIG raised its price target from $47 to $53 while maintaining a Buy rating, citing progress in trial programs and expansion opportunities. Other analysts on record set targets ranging from $40 to $80.
Investor resources and valuation tools
For investors seeking additional valuation context, the company’s Fair Value positioning and analyst price targets are available through dedicated valuation tools referenced by market services, which aggregate multiple industry models.
This article summarizes reported insider activity and related company developments based on disclosed filings and published analyst commentary.